Biotechnology Companies in France

Cell-Easy developed a unique vision of CDMO dedicated to the production of Cell-based Therapy products, this integrated concept is called CDMAO. Beyond conventional CDMO, Cell-Easy is not only focusing on Development & Manufacturing but we are positioning as a real partner for helping Biotech & Pharma to bridge the gap between preclinical and clinical development with in depth expertise on regulatory process scale-up and analytics. Cell-Easy offers customized process development, process scale-up, cGMP manufacturing and unique analytical services for immune cells (engineered CAR-T, NK, …cells, and non-engineered cells) and adult stem cells (MSCs, iPSCs and Exosomes) in both Immuno-Oncology and Regenerative Medicine fields. Cell-Easy is a trusted partner and brings today the infrastructure and know-how while ensuring your projects are delivered on time and budget. Supported by highly motivated and experienced people in the Cell Therapy field, Cell-Easy is committed to driving service excellence and actively contribute to a “Bench to Bedside” culture, putting the health care of patients at the heart of everything.

Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. Two of Antabio’s programs have received Wellcome Trust Seeding Drug Discovery Awards to date: [i] a novel, safe and efficacious inhibitor of bacterial metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections and [ii] a first-in-class inhibitor of Pseudomonas virulence to be co-administered with standard-of-care antibiotics for the long-term management of chronic respiratory infections. The company’s lead product is expected to enter the clinic in 2019 with a fast track to anticipated marketing approval. Antabio has built a best in class, international team of experts in the field and is currently seeking to raise additional funds to progress its pipeline up to the next value inflection point. Our company is also looking to in-license additional assets focused on Gram-negative antibiotic resistant therapies. Please visit www.antabio.com and follow us on Twitter @antabio

HERA-MI brings AI to improve breast cancer early detection to increase recovery rate and to optimize healthcare treatment for women. Breast Cancer is one of the leading cancer causes among women. However, when diagnosed early, patient can recover in almost 90% of cases. HERA-MI is developing a clinical decision support system based on machine learning and medical imaging processing that will improve breast cancer early detection. The system will enhance diagnosis quality and accuracy while reducing radiologists interpretation time. Moreover HERA-MI solution focuses on patient care improvement. With the more efficient breast cancer screening it allows women to be treated earlier and thus offers them higher chances for recovery.

Healshape is a regenerative medecine project. We aim at developing breast regeneration solutions by 3D bioprinting for women who had mastectomy following breast cancer.

Building a sustainable future together. Microalgae are able to propose solutions to many challenges of the positive economy. We cultivate them for various applications and animal nutrition in particular.

InFlectis BioScience is a private clinical stage company aiming at targeting and modulating interactions between proteins involved in key human pathophysiological processes. The company is developing small molecule drugs that specifically target the Integrated Stress Response (ISR). Exploiting the ISR’s natural defense offers tremendous potential for the development of a new class of therapies. Led by InFlectis, this area of research is rapidly advancing, resulting in new treatments under development for a variety of disease affecting the central nervous system (CNS), peripheral nervous system (PNS) and inflammation.

inHEART is committed to delivering the world’s most sophisticated, AI-enabled, digital twin of the heart to advance the care of patients living with cardiac disease. We believe all patients deserve access to world-class expertise that guides and optimizes treatment strategies to support improved clinical outcomes and return patients to full, healthy lives.

StarkAge Therapeutics is a privately-held biotechnology start-up, whose ambition is to delay or halt disease progression and improve quality of life of patients with age-related diseases, associated with senescent cells accumulation. It builds on its unique disease-specific exosomal / EV technology while harnessing immunotherapy approach, to address very large senescence unmet medical needs.

Susu's mission is to make healthcare affordable and accessible for Africans, in an integrated approach which connects the beneficiaries of the services, their families, and healthcare professionals. - Our services include care bundles which are packages of curative and preventative services designed to monitor the condition of chronic disease patients and pregnant women. - We also offer insurance services in partnership with insurance providers. - Our offers can be subscribed by African diaspora members on behalf of their loved ones back home

"Innovative medicine for everyone, everywhere" Listed on the Euronext stock market, Adocia is a clinical-stage biotech company specialized in the development of best-in-class medicine relying on innovative formulations of already-approved therapeutic proteins. Adocia operates in the diabetes and metabolic disease field. The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients. For more information, visit our website: www.adocia.com For careers offers, please click to the following link : http://offres.adocia.com/en

Affilogic is a private biotech company specialised in discovering and developing Nanofitins® through early-stage collaborations with worldwide industry leaders in the pharmaceutical sector. These affinity proteins are potent antibody-mimetics, exhibiting a high affinity and specificity for capture, targeting and interacting with biomolecules. Each Nanofitin® is 20 times smaller than an antibody (7 kDa) and demonstrates hyper stability. Nanofitins are easily combined with each other, antibodies and other biomolecules by simple, rapid and proven methods to design an ideal targeted molecule. Affilogic has designed Nanofitins® against 60+ targets to date, including a wide range of circulating antigens (peptides, proteins), membrane receptors for inhibition / modulation (GPCR, ion channels) and complex entities (virus-like particles, bacteria, whole cells).

Atlantic Instrument For Research (AI4R) is the world leader in digital real-time autoradiography, a new-generation imaging solutions for preclinical studies. Our company has designed a new autoradiograph: the BeaQuant. Our device uses an innovative technology (gaz detection) to give researchers a quantitative mapping of radioactivity in a sample (alpha and beta radioisotopes) . Users will experience the highest resolution in the market for autoradiographic analysis, shorter acquisition time, complete safety and unique versatility (with features such as: QWBA or dual-isotope analysis). The BeaQuant is the perfect tool to establish in vitro–in vivo correlation. If you are interested in learning more about our technology, please feel free to visit our website and contact us!

Aqemia is a pharmatech company using quantum physics and artificial intelligence to transform the drug discovery process. With a unique proprietary technology that preclude the use of experimental data, our pipeline scales the drug discovery process at an unprecedented pace, generating an exhaustive number of new drug candidates. We are hiring! Check our career website: https://jobs.lever.co/aqemia.com Blog Posts on: https://medium.com/aqemia

Biocellvia is a french company developing Intelligent Image Analysis solutions for pharmaceutical industry (Big Pharma, Biotechs, CRO) and academic communities involved in R&D. We have developed digital image analysis solutions, that enable to evaluate fully-automatically the level of efficacy of your lead molecules thanks to histological slides (in vitro, ex vivo, biopsies) in various pathologies such as: - Gastrointestinal (NASH, Liver fibrosis) - Respiratory (IPF, COPD, PAH) We provide image analysis as a service. Our technology evaluates your molecules with more accuracy, more reliability, more rapidity and less variability than traditional scoring methods. A full study (about 200 images) is performed in only a couple of days. http://biocellvia.com http://linkedin.com/company/biocellvia

Biomemory creates DNA Drives for large corporates and administrations. We organize and store data on biocompatible DNA molecules.

New ideas, new innovations, new ways of thinking for the medical device industry. We are a pharmaceutical company specialized in the discovery, clinical development, production and commercialization of innovative products in the field of regenerative medicine. At Bioxis Pharmaceuticals, we contribute to transform science into groundbreaking medical device that meet doctors need to improve the health and well-being of their patients in the field of dermatology and aesthetic medicine.

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is based in Lyon, France and Cambridge, MA, USA, and has manufacturing sites in Lyon, France, and Princeton, New Jersey, USA.. ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP).

ExactCure provides a personalized eHealth software solution. Our VISION is to live in a world where each individual has access to a personalized medication. Our MISSION is to predict the personalized effects and interactions of drugs within the body of each individual. Problem: Inappropriate medical treatments sometimes cause illness. This “iatrogenic” side effect leads to 20,000 deaths and costs €10 billion per year to the public healthcare system in France alone. Worldwide, it probably leads to more than 1 million deaths and $1 trillion in healthcare costs. Solution: Part of the solution lies in personalized medicine. That is why ExactCure created a Digital Twin. It is a non-intrusive personalized health solution able to predict the efficacy and interactions of drugs based on the specific characteristics of each individual (gender, age, weight, etc.) in real time. This electronic support (simulation, alerts, notification) will augment and secure the therapy. Our solution comes as an App for the patient’s everyday life, and as a SaaS dashboard for the health professional.

C4Diagnostics is a French-based biotech specialized in the development of in vitro diagnostic (IVD) tests for human infectious diseases C4Diagnostics' strategy for the better management of Human infectious diseases, is to develop game changing IVD tests which are significantly faster than standard methods whilst maintaining comparable or better performance. Its portfolio currently focuses on the diagnosis of Covid-19 (C4Covid-19), Legionnaires’ Disease (C4Legio LFA), urinary tract infections (C4UTI) and the development of antimicrobial susceptibility tests (C4AST). C4Diagnostics also has a business unit dedicated to environmental diagnostics, called C4Environment. It provides services for the detection of SARS-CoV-2 and other pathogens in the environment (wastewater, air, surface) and has contributed to several Covid-19 surveillance and prevention campaigns since the beginning of the pandemic. With its rapid and highly sensitive IVD tests, C4Diagnostics ambitions to become one of the main actors in the diagnosis of human infectious diseases field, by giving medical labs and healthcare professionals sensible and reliable diagnostic information in a timely manner. The game changing diagnostic solutions developed by C4Diagnostics are a leverage to fight against antibiotic resistance and curb infectious disease epidemics. contact@C4Diagnostics.com

To contact us : contact@calixar.com CALIXAR, is a biotech company specialized in the functional and native isolation of complex membrane therapeutic targets and antigens. We develop and implement chemistry and biochemistry tools to isolate in solution - with the highest purity levels - full-length membrane proteins, while keeping their structural and functional integrity. Our approach represents the opportunity for pharmaceutical companies to start and work with high quality targets or antigens before developing antibodies, formulating vaccines and/or discovering a primary lead through Structure Based Drug Design or High Throughput Screening assays. As membrane proteins represent more than 60% of pharmaceutical drug targets, to keep their native conformation during the extraction from membrane cells and solubilization is crucial. Our technological platform preserves the original structure of membrane proteins such as GPCRs, Ion channels, Transporters, Viral targets, etc.) or others native receptors acting as drug targets or antigens. As a result, this most accurate targeting helps biotechs, academic teams, pharmaceutical industries to develop highly potential drugs, bio drugs and vaccines and consequently saves significant time and money in further clinical stages. By using original chemistry and specific approaches designed on demand, we develop new tools and protocols for the identification, expression, extraction, purification and crystallization of these membrane proteins/antigens from cells or from endogenous materials (virus, bacteria, primary cells, organs, etc.). For SBDD/FBDD approaches, we carry out crystallization tests and structure determination of these native targets starting from their full-length and functional version without any point mutations or deletions. CALIXAR sets up specific R&D programs with its customers using classical and flexible business model: Fee for service, Risk sharing, Exclusivity option and Licensing out.

Flash Therapeutics is a World-class CDMO expert in lentiviral vector manufacturing : With our continuum from research to the clinic we support you throughout your projects from R&D to GMP grade. We provide purified and highly concentrated particles from small scale to large scale with the same vector specifications. Flash Therapeutics provides both integrative lentiviral vectors and non-integrative LentiFlash® particles. Lentiviral vectors : Conventional lentiviral vectors, which lead to DNA integrated into the genome, are a leading delivery method for applications which require a stable and long-term gene expression. Ideal for Gene Therapy and Immunotherapy. LentiFlash® particles : LentiFlash® combines a transient expression with a safe and efficient RNA delivery. This proprietary technology allows the delivery of multiple RNA species, without any genomic scar. Ideal for Regenerative Medicine, Gene Editing and Vaccination / Immunotherapy studies Contact us to design your project !

Created in 2001, Genoscreen provides genomic services and innovative solutions in genomics. Our offer addresses academic and industrial research teams which need to analyse DNA and explore its properties. The health, agrofood and environmental sectors are our main markets. The company’s portfolio includes: • Services in molecular biology analyses (DNA sequencing, genotyping, detection of gene mutation, metagenomics analysis in complex environment…) • Innovative kits to standardize and facilitate specific analyses (kit for microorganisms strains tracing, kit for identification of microbial community in all kinds of environment…) • Expertise and consultancy services for companies which develop projects in genomics GenoScreen also proposes custom-made trainings to people wishing to learn or improve their level about genomic analyses. GenoScreen collaborates to international research programs on Alzheimer’s disease, epidemiological surveillance of pathogens and biodiversity. Key figures: • 30 employees, doctors, engineers and technicians • 300 customers across the 5 continents • 35% of revenues coming from 30 countries outside France • 30% of revenues dedicated to R&D

GAIAGO is an Agtech company based in the region of St Malo, France. Only healthy Soils allow abundant and quality food production. We produce a new generation of Soil improvements tools, effective for all agricultures. We contribute to the farmer’s mission: cultivate and transmit a healthy and fertile Soil

Nova provides its jinkō clinical trials simulation platform to biotech and pharma companies, academic research centers and not-for-profit organizations. Jinkō® unlocks the potential of modeling & simulation to de-risk and accelerate the R&D of new therapies for the benefit of patients: identify best responders, optimise the drug's regimen, generate synthetic control arms, explore research outcomes that might not be feasible with conventional trials. Predict trial outcomes before advancing to real-world clinical trials and ultimately design studies that are more likely to succeed with Jinkō®.

OSE Immunotherapeutics is an integrated biotech company focused on developing first-in-class assets targeting cancer and inflammatory diseases. A current well-balanced first-in-class clinical pipeline including: • Tedopi® (T-cell specific immunotherapy): Company’s most advanced product; positive results for Ph 3 in NSCLC in secondary resistance after CKI failure. Other sponsored combo Ph 2 trials in solid tumors ongoing. • OSE-279 (anti-PD1) advanced preclinical stage • OSE-127 (humanized mAb antagonist of IL-7R); ongoing Ph 2 in Ulcerative Colitis; ongoing preclinical research in leukemia • VEL-101/FR104 (anti-CD28 mAb) developed in partnership with Veloxis in transplantation; ongoing Ph 1/2 in renal transplant (sponsor Nantes University Hospital); Ph 1 ongoing in the US (sponsor Veloxis). • BI 765063 (anti-SIRPα mAb on CD47/SIRPα pathway) developed in partnership with Boehringer Ingelheim in advanced solid tumors; positive Ph 1 dose escalation results in mono and in combo, in particular with anti-PD-1 antibody ezabenlimab; BI sponsored international Ph 1b clinical trial ongoing in combo with ezabenlimab alone or with other drugs in recurrent/metastatic HNSCC and HCC. OSE Immunotherapeutics expects to generate further significant value from its two proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapeutics: • BiCKI® platform focused on immuno-oncology (IO) is a bispecific fusion protein platform built on the key backbone component of anti-PD1 combined with a new immunotherapy target to increase anti-tumor efficacy. Most advanced BiCKI® candidate is targeting anti-PD1xIL-7. • Myeloid platform focused on optimizing the therapeutic potential of myeloid cells in IO & immuno-inflammation (I&I). OSE-230 (ChemR23 agonist mAb), most advanced candidate generated by the platform, with the potential to resolve chronic inflammation.

Osivax’ mission is to develop “universal” vaccines against highly-mutating viruses. Leveraging its unique oligoDOM® technology platform, OSIVAX is developing a universal vaccine for both current and future influenza infections. The Company’s universal flu vaccine candidate, OVX836 is in Phase 2a clinical development. OSIVAX is leveraging the same platform technology for the development of a universal vaccine against all existing and emerging coronavirus infections. OSIVAX is focused on providing proof-of-concept in influenza and coronavirus, and to applying its oligoDOM® platform broadly in other infectious and immune system-associated diseases.

Providing genomic analysis to everybody. SeqOne is a company focused on developing state-of-the-art genomic analysis tools for clinical applications in the fields of cancer and rare disease. The company's vision is to develop a genomic analysis system that dramatically reduces the cost and resources needed to provide accurate genomic analysis. Our aim is to make genetic testing easier and more accessible in order to accelerate the adoption of personalized medicine. SeqOne’s platform makes it possible to efficiently analyze "high resolution" next generation sequencing (NGS) data, providing a complete list of all genetic variants and prioritizing them in order of relevance. The platform uses a proprietary machine learning-based variant prioritization engine designed to identify variants that are medically relevant to each specific patient. SeqOne bioinformatics (genomic analysis algorithms) are organized by applications, which provide accurate answers to medical questions that influence patient treatment, in both constitutional and somatic pathologies. SeqOne offers applications to analyze a single-patient or an entire family to diagnose hereditary family disorders, detecting complex events such as large structural modifications or transposable elements. In the field of somatic cancer, applications can analyze tumor-only, compare healthy versus tumoral samples, or hematological cancers identifying relevant variants, such as somatic CNV, TMB, MSI, or fusion genes, as well as suggest therapeutic options. The SeqOne platform addresses the operational challenges of performing NGS analysis at scale, including secure data storage, management of process quality, and traceability needed for certification. We adopt a unique approach to process quality control that addresses ongoing process monitoring as well as changes to upstream lab procedures.

We are a clinical stage biopharmaceutical company developing developing breakthrough immunomodulatory drugs for the treatment of cancer and inflammatory diseases. We have developed two highly promising pipelines of clinical and pre-clinical candidates with a focus on cancer and auto-immune diseases: - OncoMimics™: highly effective, off-the-shelf therapeutic vaccines against cancers (EO2401, EO2463). EO2401 is in Phase 1/2 clinical trials in patients with glioblastoma and adrenal tumors. EO2463 is in a Phase 1/2 clinical trial for indolent non-Hodgkin B-cell lymphomas. - EndoMimics™: a pipeline of next generation bioactives acting like human hormones or cytokines for the treatment of immune diseases. EB1010, the lead candidate, is a potent local inducer of IL-10 designed to provide improved therapeutic outcomes for patients with IBD. In addition, Enterome’s clinical candidate sibofimloc (also referred to as TAK-018) is advancing through a Phase 2 clinical trial in post-operative Crohn’s disease. Sibofimloc has been partnered with Takeda globally, with Enterome retaining a significant profit share in the US.

Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases. We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases. Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success will provide rapid validation of our ALIGATER platform.

YSOPIA Bioscience is a clinical-stage biotech company developing cutting-edge biotherapies based on the gut microbiome. Our goal is to bring safe & efficient solutions to patients with high unmet medical needs.

Created in 2003, Modul-Bio is an innovative company specialized in IT solutions for biological sample management providing barcoding systems, LIMS (Laboratory Information Management System) software and collaborative tools for sharing biological sample collections.

Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need. Innate has been a pioneer in the understanding of natural killer cell (NK cell) biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca. Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Solution d'éclairage intelligente pour l’optimisation de la croissance des plantes et la consommation énergétique associée.

L'Alliance Innovation Santé, ALLIS-NA, vise à regrouper l'ensemble des forces industrielles, académiques, institutionnelles et hospitalières autour de valeurs communes au profit des patients. Nos missions : Représenter et Animer l’Écosystème Santé en Nouvelle-Aquitaine pour soutenir son développement économique et Territorial : - Être un “partenaire” pour les professionnels d’innovation SANTE - Faciliter les connections et les alliances - Faire rayonner et représenter les professionnels de la filière - Accélérer la création de valeur et la croissance des entreprises N'hésitez pas à nous contacter et à rejoindre le réseau !

Depuis son fondement en janvier 2016, Woodlight est une Startup de recherche et développement de nouvelles biotechnologies. Son objectif est de rendre les villes plus vertes en répondant à leurs problèmes de pollution, de manque de verdure et de forte consommation en énergie. Pour répondre aux besoins grandissants d’éclairage durable et d’économie d’énergie des villes, Woodlight propose de développer un procédé permettant de rendre des plantes, bioluminescentes. Ces plantes pourront être utilisées comme lampes d’ambiance pour la décoration intérieure. On peut alors imaginer autant un lierre, qu’un ficus ou encore une orchidée luminescente. Au-delà de ces utilisations, ces plantes pourraient être utilisées comme alternative végétale aux lampadaires des villes ou comme balise dans des parcs et jardins. Les applications sont vastes et nous vous laissons imaginer leurs potentiels !

XenTech is Biotech/Contract Research Organization (CRO) dedicated to translational research in oncology which offers preclinical services to evaluate the anti-cancer potential of drug candidates (PDX, CDX,...) In addition, XenTech develops internal R&D programs to correlate drug response with molecular features of tumors and identify cancer biomarkers and therapeutic targets.

CNRS UMR8199 is a French research institute based in Lille, specializing in the study of metabolic diseases and their genetic causes.

Our team, led by Pr. Philippe Froguel, focuses on understanding the molecular mechanisms behind diseases like diabetes and obesity, with the ultimate goal of developing more effective prevention and treatment strategies.

We conduct cutting-edge research in genomics and molecular physiology, contributing to a deeper understanding of these complex conditions and paving the way for personalized medicine. We are a key player in the **biotechnology research** sector, collaborating with leading institutions globally.

Established in 1995, CNRS UMR8199 has grown to a team of 11 researchers, furthering our commitment to advancing scientific knowledge and improving patient outcomes.

Orano Med is a French research and development company specializing in the production of high-purity lead-212 (Pb-212), a rare radioactive isotope, and driving innovation in targeted cancer therapies.

Based on a program initiated in 2005, Orano Med has pioneered the targeted alpha therapy (TAT) approach, recognizing and destroying cancer cells while minimizing harm to healthy tissue.

Leveraging Macrocyclics, Inc., a key component of Orano Med, the company operates a robust industrial platform for Pb-212 production and maintains a strong pipeline of research and development, including 18 clinical trials and over 30 patents.

With 220 employees across France and the United States, Orano Med is committed to advancing the field of nuclear medicine and improving patient outcomes through cutting-edge radiotherapeutic solutions.

Iktos is a Paris, France-based artificial intelligence company revolutionizing drug discovery.

We specialize in applying generative AI to medicinal chemistry, enabling pharmaceutical companies and research institutions to design and optimize molecules in silico. Our proprietary SaaS platforms, Makya™ and Spaya™, combined with our AI-driven robotics platform, dramatically accelerate the entire drug development process – from initial design to synthesis and testing.

Iktos is at the forefront of innovation, leveraging cutting-edge technology to reduce R&D timelines and increase the success rate of new drug candidates, particularly in oncology and autoimmune diseases. We are proud to have received significant investment and recognition, including a recent EIC Accelerator grant, demonstrating our commitment to transforming the future of drug discovery.

Ambiotis is a pre-clinical CRO specialized in the study of inflammatory processes and the active end of inflammation, called resolution. Resolution is now recognized as the necessary biological process to stop inflammation and restore homeostasis in tissues. This recent approach makes possible to study the inflammation process in a completely innovative and differentiating way. Ambiotis proposes services adapted to pharmaceutical, dermo-cosmetic, agro- food/nutraceutical industries to evaluate the potential of their molecules at preclinical or clinical stages of development. Ambiotis thus helps them to put faster on the market more efficient and innovative compounds on immuno-inflammatory processes. With more than 10 years of experience, Ambiotis has acquired a solid expertise in understanding the molecular mechanisms controlling these phenomenons . Ambiotis has built a strong expertise in both cell/animal models and analytical measurement. This combination is the key to ensure a full understanding and provide proof of efficacy or proof of concept for the development of new innovative products.

ENYO Pharma is a clinical stage company with an innovative approach inspired by viruses. Our biotech mimics virus strategy to modulate host cellular functions with multiple applications. We develop new drug candidates in multiple indications such as infectious diseases (e.g. HBV), metabolic diseases (e.g. NASH) and oncology. Our main candidate Vonafexor (EYP001, FXR agonist) is in Phase 2 for both chronic hepatitis B and Non-Alcoholic Steato-Hepatitis. Our second candidate, EYP002, is currently in preclinical studies. Initially developed against influenza virus, it has a mitochondrial cellular target which leads ENYO Pharma to explore new indications such as oncology or metabolic diseases. Thanks to the MIMESIS project, funded by European Union’s Horizon 2020 Research and Innovation Program, ENYO Pharma has a portfolio of early molecules for various indications (RSV, Immunogenic Cell Death, Zika virus, rhinovirus, influenza virus and Mycobacterium tuberculosis) ENYO Pharma is also a member of the CARE consortium (Corona Accelerated R&D in Europe), the largest European research initiative addressing the drug discovery challenges of COVID-19, funded by IMI 2 JU. ENYO Pharma is currently based in Lyon, France and in Melbourne, Australia.

Emulseo is a startup company dedicated to the design and production of high-quality formulations for microfluidic applications. Our service is based upon long-term know-how and expertise in the field of microfluidics for pharmaceutical, biotech and chemical industry. Check out our website to discover our choice of fluorinated surfactants, fluorinated oils, surface treatments and many more products to come! Whatever your application, we have a dedicated team of scientists focused on working closely with you to provide products and custom-made solutions of the highest quality and guide you through your projects.

Faircraft develops a highly sustainable, lab-grown alternative to animal leather, based on advanced tissue engineering and material science techniques.

GOLIVER THERAPEUTICS is a spin-off from the INSERM and University of Nantes (CRTI UMR1064-ITUN-Nantes Hospital), focused on developing cell-based Advanced Therapy Medicinal Products (ATMP) to respond to an urgent unmet medical need in transplantation. GOLIVER THERAPEUTICS aims to become a Worldwide leader inregenerative medicine in providing the first cell-based therapy product for life-threatening liver failures.

Auto-transfusion specialist through innovative technology for the separation of blood components.

CardioRenal uses the advanced technologies to develop digital therapeutic solutions.

Through the lens of predictive medicine, MEDICREA® leverages its proprietary software analysis tools with big data and machine learning technologies supported by an expansive collection of clinical and scientific data. The Company is well-placed to streamline the efficiency of spinal care, reduce procedural complications and limit time spent in the operating room. Operating in a $10 billion marketplace, MEDICREA® is a Small and Medium sized Enterprise (SME) with 210 employees worldwide, which includes 50 who are based in the U.S. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D-printed titanium patient-specific implants. For further information, please visit: medicrea.com

Mnemo Therapeutics is a biotechnology company focused on discovering and developing immune based therapies, including powerful cell therapies, that create accessible cures for solid tumors and blood cancers. Its EnfiniT platform, a groundbreaking drug discovery engine, leverages a new class of antigens with greater tumor specificity and a suite of technologies to significantly improve T cell memory, persistence, and sensitivity. The result is dramatic improvement in the body’s immune response to overcome disease. Mnemo is built by a global team of scientists and biotech leaders united in their mission to create the most powerful immune therapies to deliver accessible cures for all patients in need.

PathoQuest helps biopharmaceutical developers and manufacturers get their therapies to market with our leading expertise in GMP NGS-based biosafety testing and characterization services. As innovator companies continue to bring exciting novel therapies to market, there is a critical need for alternative biosafety and characterization strategies. This is especially the case for life-changing cell and gene therapies, as well as novel viral vaccines. Classical testing approaches, such as cell based assays, are often challenging to implement due to high volume requirements, as well as compatibility issues. Biosafety testing and characterization are key regulatory requirements for the release of biologic therapies. Therefore, alternative methods which can address these issues are of intense interest. There is also a drive from across industry and regulators to reduce, and eventually eliminate the use of animal models used in biosafety testing. The genomic approach of Next Generation Sequencing (NGS) can solve many of the challenges that are faced by developers and manufacturers, such as lower volume requirements and incompatibility with cell-based assays From our origins within the Institut Pasteur, PathoQuest is leading the way in expertise for the provision of GMP NGS based biosafety testing. Our expertise is underlined with over 20 peer reviewed publications on NGS applications in biosafety testing; as well as active participation in industry groups such as PDA, ADVTIG, CAACB and EFPIA. PathoQuest are committed to bringing this game-changing genomic approach to biopharmaceutical developers and manufacturers. PathoQuest has a global footprint, with operations in Europe (Paris) and North America (Wayne, PA); and have provided NGS biosafety testing services to over 100 of the top biopharmaceutical companies globally. Why not get in touch to see how we can help you with your biosafety testing strategy?